These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 21824093)
21. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization. Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251 [TBL] [Abstract][Full Text] [Related]
22. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Paris RM; Kim JH; Robb ML; Michael NL Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348 [TBL] [Abstract][Full Text] [Related]
24. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Hu H; Eller MA; Zafar S; Zhou Y; Gu M; Wei Z; Currier JR; Marovich MA; Kibuuka HN; Bailer RT; Koup RA; Robb ML; Michael NL; Kim JH; Ratto-Kim S Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13439-44. PubMed ID: 25197078 [TBL] [Abstract][Full Text] [Related]
25. Adenoviruses as vectors for HIV vaccines. Gómez-Román VR; Robert-Guroff M AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567 [TBL] [Abstract][Full Text] [Related]
26. HIV-1 T-cell vaccines: evaluating the next step. Pantaleo G Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842 [No Abstract] [Full Text] [Related]
27. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS; Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336 [TBL] [Abstract][Full Text] [Related]
28. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Shiver JW; Emini EA Annu Rev Med; 2004; 55():355-72. PubMed ID: 14746526 [TBL] [Abstract][Full Text] [Related]
30. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199 [TBL] [Abstract][Full Text] [Related]
31. Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques. Murakowski DK; Barton JP; Peter L; Chandrashekar A; Bondzie E; Gao A; Barouch DH; Chakraborty AK Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33514660 [TBL] [Abstract][Full Text] [Related]
32. Ebola virus vaccine: benefit and risks of adenovirus-based vectors. Mennechet FJ; Tran TT; Eichholz K; van de Perre P; Kremer EJ Expert Rev Vaccines; 2015; 14(11):1471-8. PubMed ID: 26325242 [TBL] [Abstract][Full Text] [Related]
33. HIV vaccines in infants and children. Lambert JS Paediatr Drugs; 2005; 7(5):267-76. PubMed ID: 16220994 [TBL] [Abstract][Full Text] [Related]
34. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine. Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058 [TBL] [Abstract][Full Text] [Related]
35. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic and prophylactic DNA vaccines for HIV-1. Ramirez LA; Arango T; Boyer J Expert Opin Biol Ther; 2013 Apr; 13(4):563-73. PubMed ID: 23477730 [TBL] [Abstract][Full Text] [Related]